- Home
- VNDA vs ACIU Comparison
VNDA vs ACIU Comparison
Compare VNDA & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNDA
- ACIU
- Stock Information
- Founded
- VNDA 2002
- ACIU 2003
- Country
- VNDA United States
- ACIU Switzerland
- Employees
- VNDA N/A
- ACIU N/A
- Industry
- VNDA Biotechnology: Pharmaceutical Preparations
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- VNDA Health Care
- ACIU Health Care
- Exchange
- VNDA Nasdaq
- ACIU Nasdaq
- Market Cap
- VNDA 270.0M
- ACIU 294.9M
- IPO Year
- VNDA 2006
- ACIU 2016
- Fundamental
- Price
- VNDA $4.51
- ACIU $2.65
- Analyst Decision
- VNDA Strong Buy
- ACIU Strong Buy
- Analyst Count
- VNDA 2
- ACIU 2
- Target Price
- VNDA $15.50
- ACIU $12.00
- AVG Volume (30 Days)
- VNDA 499.8K
- ACIU 147.0K
- Earning Date
- VNDA 02-05-2025
- ACIU 03-13-2025
- Dividend Yield
- VNDA N/A
- ACIU N/A
- EPS Growth
- VNDA N/A
- ACIU N/A
- EPS
- VNDA N/A
- ACIU N/A
- Revenue
- VNDA $190,858,000.00
- ACIU $48,505,404.00
- Revenue This Year
- VNDA $5.60
- ACIU $86.72
- Revenue Next Year
- VNDA $42.85
- ACIU $118.28
- P/E Ratio
- VNDA N/A
- ACIU N/A
- Revenue Growth
- VNDA N/A
- ACIU 4097200.00
- 52 Week Low
- VNDA $3.46
- ACIU $2.25
- 52 Week High
- VNDA $6.75
- ACIU $4.98
- Technical
- Relative Strength Index (RSI)
- VNDA 42.95
- ACIU 39.10
- Support Level
- VNDA $4.77
- ACIU $2.56
- Resistance Level
- VNDA $4.95
- ACIU $2.83
- Average True Range (ATR)
- VNDA 0.15
- ACIU 0.16
- MACD
- VNDA -0.03
- ACIU -0.00
- Stochastic Oscillator
- VNDA 31.82
- ACIU 16.85
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.